DEP radiopharmaceutical data supports patent application

Summary by 6ix AI

Starpharma Holdings Limited has announced the filing of a new patent application for its DEP® technology in radioligand therapy, following promising preclinical results that demonstrate a unique radiopharmaceutical profile. The data indicates improved biodistribution, enhanced tumor uptake, and reduced off-target effects, suggesting a potential for better therapeutic outcomes compared to existing treatments. CEO Cheryl Maley emphasized that this patent strengthens Starpharma's intellectual property position and supports their strategy for developing and partnering multiple DEP® radiopharmaceutical programs. The announcement highlights the growing opportunities in the radiopharmaceutical sector, which is attracting significant interest from global pharmaceutical companies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries